Evaluation of carrier added and no carrier added 90Y-EDTMP as bone seeking therapeutic radiopharmaceutical

Abstract

The optimum conditions to label ethylenediaminetetramethylene phosphonate (EDTMP) compound with 90y as a potential candidate for bone metastases therapy were investigated. Yttrium-90 is a pure β-emitter and can be obtained by 89y (n,γ) 90y nuclear reaction in a reactor or from an in-house generator system (90sr→90y). The preparation of 90Y-EDTMPis described using 90y, which was obtained from neutron radiation of y2o3 as well as from a laboratory scale organic resin-based 90sr→90y generator. Because of the adiolabeling yield of 90Y-EDTMP on ligand/metal molar ratio, incubation time and ph was evaluated. Under optimum parameters, the radiolabeling yields of 90Y-EDTMPwere <95% for no-carrier-added as well as carrier-added 90y. The biodistribution of no-carrier-added and carrier-added 90YEDTMPcomplexes in rats was identical. The results indicate that 90y (carrier-added)-edtmp is also an effective bone pain palliation agent because of its rapid blood clearance, greater uptake in bones and little absorption in soft tissues.